Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Augury1 inhibitor
- Development stage
- Preclinical
- Lead developer
- Gordian Biotechnology
- Modality
- Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Augury1 inhibitor is an experimental adipose-targeted gene therapy developed by Gordian Biotechnology for the treatment of obesity and metabolic disorders. Discovered using an in vivo pooled screening platform in visceral adipose tissue, Augury1 is a novel genetic target whose knockdown in mature adipocytes activates lipolysis, upregulates lipid droplet structural proteins, and promotes fatty acid/glyceride futile cycling. Delivered as an AAV-based artificial miRNA, Augury1 inhibitor has demonstrated significant efficacy in diet-induced obese (DIO) mouse models, driving weight loss and improving glucose tolerance. When combined with the GLP-1 receptor agonist semaglutide, Augury1 inhibition acts additively to enhance weight loss and prevent weight regain following semaglutide cessation, while maintaining persistent insulin sensitization.
- Other names
- Augury1 knockdown therapyAugury-1 knockdown therapyAugury 1 knockdown therapyAugury1 miRNA therapyAugury-1 miRNA therapyAugury 1 miRNA therapy
02
Targets
ECRG4 (Augurin)
Beyond the preview
Go deeper on Augury1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Augury1 inhibitor.